Thermo Fisher Scientific on Tuesday announced the introduction of numerous dPCR liquid biopsy assays for its Applied Biosystems Absolute Q dPCR system, as well as a custom design tool to simplify cancer research.
The company said that it has introduced more than 50 Absolute Q Liquid Biopsy Assays to run on the fully integrated digital PCR system, which is designed to provide results within 90 minutes with minimal hands-on time.
The assays are predesigned for research to identify genetic mutations, including challenging cancer hotspot mutations, and to help enable simplification of liquid biopsy workflows, Thermo Fisher said.
The firm's liquid biopsy portfolio, which includes 20 previously developed assays, covers common genes such as EGFR, KRAS, NRAS, PIK3CA, and PK53.
Thermo Fisher added that its Digital PCR Custom Assay Design tool enables academic and clinical research laboratories to quickly generate custom dPCR assays with no design experience necessary.
The design tool and assays are suitable for both translational and clinical research settings.